3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Neoplasm Metastasis
8
Esophageal Neoplasms
8
Carcinoma, Hepatocellular
7
Melanoma
6
Lung Neoplasms
6
Neoplasms
5
Breast Neoplasms
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Nasopharyngeal Carcinoma
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Breast Neoplasms, Male
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms
1
Pleural Mesothelial Neoplasm
1
Interventions
Cisplatin
6
pembrolizumab
5
Nivolumab
5
palbociclib
4
durvalumab
4
Pemetrexed
4
atezolizumab
3
abemaciclib
3
Fulvestrant
3
Carboplatin
3
Anastrozole
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
relatlimab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Radiosurgery
2
Paclitaxel
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Bevacizumab
2
AZD9833
2
trametinib
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Immunotherapy
×
1 year
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled